Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Incyte presented positive Phase 1 data for INCA033989, a first-in-class mutCALR-targeted antibody, at the EHA 2026 Congress, showing rapid and durable clinical responses in patients with myelofibrosis and essential thrombocythemia. In essential thrombocythemia, 70% of patients achieved complete hematologic response with a median onset of ~2 weeks, while in myelofibrosis, the drug demonstrated significant spleen volume reductions and anemia improvements alongside consistent molecular activity.
Key figures
- Drug Name
- INCA033989
- Phase Of Trial
- Phase 1
- Et chr rate
- 70%
- Mf svr35 rate
- 39%
- Et chr phr rate
- 87%
- Et median time to chr
- ~2 weeks
- Mf vaf reduction rate
- 89%
- Mf anemia response rate
- 60%
- Et patients on treatment
- 95%
- Mf patients on treatment
- 84%
- Et median response duration
- 23 weeks
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.